Pfizer raises full-year outlook as new products drive growth
Pfizer lifts its 2026 revenue guidance to $62‑64 billion, citing strong sales of Seagen, Biohaven and other newer products while COVID sales fall.
Topic
CFO
The latest CFO news, explained clearly: what happened, why it matters and what comes next. Every NewsClearly story on CFO, newest first.
1 story